However, the quality of research evidence supporting the efficacy of many adjuvant technologies or treatments (often termed ‘add-ons’) in unselected patient populations is under increasing scrutiny, as are the main reasons for their use. In 2016, a report on IVF treatment commissioned by the BBC (Spencer et al., 2016) implied that the primary drive behind the use of almost 30 ‘unproven’ add-on treatments was not to improve outcomes for patients, but to increase the profitability of the clinics offering them, and this view remains prevalent (Harper et al., 2017, Repping et al., 2019).

https://www.rbmojournal.com/article/...19)30381-5/pdf